Thanks Waynesworld, as always, great summary. There is no doubt that big Pharma in the DMD space are aware of our P2 results and some are busily doing due diligence on our company. The recent Morgan's and Wilson's reports should accelerate this process as clearly both have done their homework, (derisked range $1.3 - $1.8). Now with Sarepta out of the picture, I think we can safely project a derisked share price over $2. So when the penny finally drops we should see a significant rerate to at least 50 cents prior to P2b and if it's a successful open label study, $1 by years end... time to accumulate and hold. Exciting time ahead...
- Forums
- ASX - By Stock
- PER
- Sarepta gene therapy study missed key target in Duchennes
Sarepta gene therapy study missed key target in Duchennes, page-116
-
- There are more pages in this discussion • 298 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.6¢ |
Change
0.001(1.18%) |
Mkt cap ! $77.53M |
Open | High | Low | Value | Volume |
8.5¢ | 8.8¢ | 8.4¢ | $18.63K | 218.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 8.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.6¢ | 46681 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 30000 | 0.085 |
1 | 29206 | 0.083 |
2 | 96888 | 0.082 |
1 | 38100 | 0.081 |
4 | 217800 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.086 | 46681 | 1 |
0.088 | 96794 | 4 |
0.089 | 135000 | 2 |
0.090 | 443317 | 5 |
0.091 | 108000 | 1 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |